Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products

LONDON, April 29, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products

http://www.reportbuyer.com/pharma_healthcare/healthcare/healthcare_acquired_infection.html

REASONS FOR DOING THE STUDY

The objective of this study is to provide an in-depth analysis and forecast of selected areas of the global healthcare-acquired infections (HAI) market. For purposes of this report, HAI includes hospitals, nursing homes, outpatient surgery centers and dialysis centers. The focus of this report is on selected devices, pharmaceuticals and environmental products currently used or under development for treatment of viral, bacterial and fungal infections.
The global market for HAI products is estimated at between $12 billion and $17 billion in 2012 (depending on the products included in the study) with high single-digit growth through 2018. The North American market and in particular the U.S. holds the largest market share of any region at 45% to 50% and the fastest growing regions for HAI treatments are Brazil and the Asian region, particularly China and India.

STUDY GOALS AND OBJECTIVES

Healthcare-acquired infections are viral, bacterial or fungal infections that patients acquire after they are admitted to a healthcare facility. Patients can acquire these infections from routine care; surgery; or as a complication from the use of medical devices such as ventilators, catheters and intravenous lines.
This report is designed to investigate the global HAI market by treatment area and by type of treatment, with supporting tables and figures to illustrate projected growth. Within each type of treatment, regional analyses will focus on the Americas (i.e., Canada, U.S., Mexico, Central America and South America); EMRA (i.e., Europe, the Middle East, Russia and Africa); and Asia (i.e., Japan, China, India, other Western Pacific countries such as Australia and New Zealand and other Southeast Asian countries).

SCOPE AND FORMAT

This report offers forecasts by treatment segment and type of treatment, from 2013 through 2018, including supporting analyses for projections.
The main market segments are analyzed by pharmaceutical treatments, environmental treatments and infection control devices/products.
This report is a valuable tool for anyone assessing the HAI market and attempting to devise a strategy to successfully compete in this market. This report provides background on the structure of the HAI market and the chief challenges and opportunities it faces. It offers the information needed to understand the current market and to address the emerging one.
The report is an invaluable tool for business planners, acquisition specialists, licensing strategists, product managers, market research analysts, investing consultants and others interested in the HAI market, its products, its participants and its future.

METHODOLOGIES AND INFORMATION SOURCES

Information for this report was obtained from a variety of primary and secondary research sources, including industry analysts, annual reports and agencies and organizations such as the U.S. Securities and Exchange Commission (SEC), the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), the U.S. National Institutes of Health (NIH), American Hospital Association (AHA), Infectious Disease Society of America (IDSA), American Society of Heating, Refrigerating and Air Conditioning Engineers (ASHRAE), National Institute of Allergy and Infectious Diseases (NIAID), the National Hospital Discharge Survey (NHDS) and government agencies outside the U.S. Secondary sources include literature searches, journal articles, product literature and press releases.
When precise information was not available, a consensus has been made using reasonable assumptions and estimates based on historical data.

ANALYST CREDENTIALS

Peggy S. Lehr is the BCC Research Analyst of this report. Ms. Lehr holds a BS in Journalism from the University of Colorado, Boulder and an MS in Communication from the University of Denver. Ms. Lehr has worked within the publishing industry for both for-profit and not-for-profit organizations and she specializes in marketing reports on the medical industry. Her latest report, HLC078B Magnetic Resonance Imaging: The Global Market, was published in September 2013.

REPORT HIGHLIGHTS

This report provides:
• Forecasts of the markets for healthcare-acquired infection (HAI) devices, pharmaceuticals, and therapies by treatment segment and treatment type, including supporting analyses for projections
• Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018
• Valuable tools for anyone assessing the HAI market and attempting to devise a strategy to successfully compete in the industry
• Background on the structure of the HAI market and the opportunities available as well as the chief challenges it faces
• Information needed to understand the current market and to address the emerging market
• Comprehensive company profiles of key players in the market.

TABLE OF CONTENTS

CHAPTER 1 INTRODUCTION 2

REASONS FOR DOING THE STUDY 2
STUDY GOALS AND OBJECTIVES 2
SCOPE AND FORMAT 2
METHODOLOGIES AND INFORMATION SOURCES 3
ANALYST CREDENTIALS 3
RELATED BCC REPORTS 3
BCC ONLINE SERVICES 3
DISCLAIMER 4

CHAPTER 2 SUMMARY 6

SUMMARY TABLE GLOBAL MARKET FOR SELECTED HAI TREATMENTS, THROUGH
2018 ($ MILLIONS) 7
SUMMARY FIGURE GLOBAL MARKET SHARES OF HAI TREATMENTS BY
GEOGRAPHICAL AREA, 2013 AND 2018 (%) 8

CHAPTER 3 GLOBAL HAI OVERVIEW 10

RISKS FOR ACQUIRING HAI 10
MOST COMMON HEALTHCARE-ASSOCIATED INFECTIONS 11
TABLE 1 CAUSES AND TYPES OF HEALTHCARE-ACQUIRED INFECTIONS 12
GRAM-POSITIVE BACTERIA 13
S. AUREUS 13
Transmission Routes 13
MRSA 13
Transmission Routes 14
PNEUMONIA 14
Pseudomonas Aeruginosa 14
Hospital-Acquired Pneumonia (HAP) 14
K. Pneumonia 14
CLOSTRIDIUM DIFFICILE 15
MYCOBACTERIUM TUBERCULOSIS 15
TB Funding 15
Scope of Infection 15
Multi-Drug Resistant Tuberculosis (MDR-TB) 16
E. COLI 16
UTI Treatment Options 16
GASTROENTERITIS-CAUSING BACTERIA 17
Treatment Options 17
VANCOMYCIN-RESISTANT ENTEROCOCCI (VRE) 17
Types of VRE 17
LEGIONELLA BACTERIA 17
Treatment Options 18
GRAM-NEGATIVE BACTERIA 18
PSEUDOMONAS AERUGINOSA 18
ACINETOBACTER BAUMANNII 18
CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE) 19
VIRAL INFECTIONS 19
HEPATITIS B AND C 19
Scope of Infection 19
Treatment 20
HIV 20
Treatment 20
NOROVIRUS 20
INFLUENZA VIRUS 21
Influenzavirus A, B, C 21
Transmission 21
Symptoms 21
Treatment 21
FUNGAL INFECTIONS 22
ASPERGILLUS INFECTIONS 22
Treatment 22
YEAST INFECTIONS 22
Candida Infections 23
PREVENTING HAI 23
DETERMINING THE MODE OF TRANSMISSION 23
ROLES OF HEALTHCARE INSTITUTIONS AND INFECTION CONTROL
INDIVIDUALS 24
TABLE 2 SELECTED RESPONSIBILITIES OF INFECTION CONTROL TEAM MEMBERS 24
COMPONENTS OF A HAI SURVEILLANCE SYSTEM 26
TABLE 3 MAIN STEPS AND COMPONENTS IN DEVELOPING AN EFFECTIVE INFECTION
CONTROL SURVEILLANCE SYSTEM 26
HEALTHCARE INFECTION POINTS OF GENERATION 27
HOSPITAL 27
Hospital Surgical Procedures 27
AMBULATORY SURGERY CENTERS IN THE U.S. 27
Infection Control in ASCs 28
DIALYSIS CENTERS 28
Transmission of VRE in Dialysis Centers 28
Hepatitis Transmission in Dialysis Centers 29
ASSISTED LIVING/LONG-TERM CARE FACILITIES 29
PROACTIVE TREATMENTS 29
THE IMPORTANCE OF HAND WASHING 29
CDC RECOMMENDATIONS FOR PREVENTION 30
TABLE 4 CDC MEASURES FOR PREVENTION OF HEALTHCARE-ACQUIRED
INFECTIONS 30
TABLE 5 GOALS TO REDUCE HAI IN U.S. HOSPITALS BY 2013 32
TABLE 6 DECREASE IN HAI IN U.S. HOSPITAL SETTINGS, 2008–2010 (%) 32
ENVIRONMENTAL CONTROLS 32
DEVICE DESIGN 33
HUMAN AND MONETARY COSTS OF HAI 33
U.S. HEALTHCARE SPENDING 33
U.S. HEALTHCARE SPENDING AND HAI 33
EMRA 34
ASIA 34
India 34
Japan 34
Rate of Infection 35
CHINESE MARKET 35
CHANGES IN THE INDUSTRY 36
TABLE 7 SELECTED MERGERS AND/OR ACQUISITIONS, 2008-2013 ($ MILLIONS) 36

CHAPTER 4 HAI PHARMACEUTICAL MARKET 39

PHARMACEUTICALS USED FOR HAI 39
TABLE 8 PROJECTED GLOBAL MARKET FOR HAI PHARMACEUTICALS BY TYPE,
THROUGH 2018 ($ MILLIONS) 39
VIRAL HAI PHARMACEUTICALS 40
TABLE 9 SELECTED VIRAL HAI PHARMACEUTICALS BY NAME, INDICATION AND
MANUFACTURER, 2010 40
VIRAL PHARMACEUTICAL MARKET BY COMPANY 41
FIGURE 1 ESTIMATED GLOBAL MARKET SHARES OF HEPATITIS PHARMACEUTICALS
TO TREAT HAI BY COMPANY, 2012 (%) 41
FIGURE 2 ESTIMATED GLOBAL MARKET SHARES OF HIV PHARMACEUTICALS TO
TREAT HAI BY COMPANY, 2012 (%) 42
FIGURE 3 GLOBAL MARKET SHARES OF HAI VIRAL PHARMACEUTICALS BY TYPE OF
DISEASE, 2012 (%) 43
VIRAL PHARMACEUTICAL MARKET BY CONDITION 43
TABLE 10 PROJECTED GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT VIRAL
HAI BY CONDITION, THROUGH 2018 ($ MILLIONS) 44
BACTERIAL HAI 44
THE THREAT OF ANTIBIOTIC RESISTANCE 44
THE MICROBIOLOGY OF BACTERIAL RESISTANCE 44
MECHANISMS OF RESISTANCE 45
METHODS OF RESISTANCE 45
Beta-Lactamase Production 45
Importing Resistance from Other Organisms 46
Alteration of Binding Sites to Circumvent Anti-infective Effectiveness 47
Antibiotic Discharge 47
PRIMARY REASONS FOR ANTIBIOTIC RESISTANCE 47
Incomplete Course of Prescribed Medicine 47
Overuse of Broad-Spectrum Antibiotics 47
Antibiotics and Food Production Animals 48
Patient Pressure 48
RESISTANCE BY CLASS OF ANTIBIOTIC 48
TABLE 11 ANTIBIOTIC RESISTANT ORGANISMS AND DRUG CLASSES AFFECTED 49
BACTERIAL HAI PHARMACEUTICALS 49
TABLE 12 SELECTED BACTERIAL HAI PHARMACEUTICALS BY NAME, INDICATION
AND MANUFACTURER, 2012 49
CLASSES OF DRUGS 50
Aminoglycosides 50
B-lactam Antibiotics 51
Cephalosporins 51
Glycopeptides 52
Lincosamides 52
Lipopeptides 52
Carbapenems 52
Penicillins 53
Polypeptides 53
Macrolides 53
Quinolones 53
Tetracyclines 54
Sulfonamides 54
Other Formulations 54
New Treatment for Tuberculosis 54
GLOBAL MARKET SHARE FOR BACTERIAL PHARMACEUTICALS BY COMPANY 54
FIGURE 4 ESTIMATED GLOBAL MARKET SHARES OF HAI BACTERIAL
PHARMACEUTICALS BY COMPANY, 2012 (%) 54
TABLE 13 PROJECTED GLOBAL MARKET FOR TO TREAT BACTERIAL HAI, THROUGH
2018 ($ MILLIONS) 56
FUNGAL HAI PHARMACEUTICALS 56
TABLE 14 SELECT LISTING OF PHARMACEUTICALS TO TREAT FUNGAL INFECTIONS
BY NAME, TYPE AND MANUFACTURER, 2012 56
TABLE 15 PROJECTED GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT
FUNGAL HAI, THROUGH 2018 ($ MILLIONS) 57
FIGURE 5 GLOBAL MARKET SHARES OF PHARMACEUTICALS TO TREAT FUNGAL HAI
BY COMPANY, 2012 (%) 57
GLOBAL OPPORTUNITIES 58
GLOBAL GROWTH RATES FOR PHARMACEUTICALS 58
ROLE OF EMERGING COUNTRIES IN GLOBAL MARKETS 58
PHARMACEUTICAL SALES IN EMERGING NATIONS 58
REGIONAL ANALYSIS 59
TABLE 16 PROJECTED GLOBAL MARKET FOR HAI PHARMACEUTICALS BY REGION,
THROUGH 2018 ($ MILLIONS) 59
AMERICAS 59
TABLE 17 PROJECTED AMERICAS MARKET FOR PHARMACEUTICAL PRODUCTS TO
CONTROL HAI BY REGION, THROUGH 2018 ($ MILLIONS) 60
TABLE 18 PROJECTED AMERICAS MARKET FOR PHARMACEUTICAL PRODUCTS
DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 ($
MILLIONS)
60
FIGURE 6 AMERICAS HAI PHARMACEUTICAL MARKET SHARES BY DISEASE TYPE,
2013 AND 2018 (%) 60
EMRA 61
TABLE 19 PROJECTED EMRA MARKET FOR PHARMACEUTICAL PRODUCTS TO
CONTROL HAI BY REGION, THROUGH 2018 ($ MILLIONS) 62
TABLE 20 PROJECTED EMRA MARKET FOR PHARMACEUTICAL PRODUCTS DESIGNED
TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS BY TYPE, THROUGH 2018 ($
MILLIONS)
63
FIGURE 7 EMRA HAI PHARMACEUTICAL MARKET SHARES BY DISEASE TYPE, 2013
AND 2018 (%) 64
ASIA 64
Hepatitis in Asian Region 65
Hepatitis in Japan 65
Hepatitis in China 65
TABLE 21 PROJECTED ASIAN MARKET FOR PHARMACEUTICAL PRODUCTS TO
CONTROL HAI, THROUGH 2018 ($ MILLIONS) 65
TABLE 22 PROJECTED ASIAN MARKET FOR PHARMACEUTICAL PRODUCTS
DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS BY TYPE, THROUGH
2018 ($ MILLIONS)
66
FIGURE 8 ASIAN HAI PHARMACEUTICAL MARKET SHARES BY DISEASE TYPE, 2013
AND 2018 (%) 66

CHAPTER 5 HAI ENVIRONMENTAL TREATMENT MARKET 69

GLOBAL HAI ENVIRONMENTAL TREATMENT MARKET 69
TABLE 23 PROJECTED GLOBAL MARKET FOR ENVIRONMENTAL PRODUCTS
DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 ($
MILLIONS)
69
AIR TREATMENT 69
ROOM FILTRATION SYSTEMS 70
ROOM PRESSURIZATION 70
HYDROGEN PEROXIDE VAPOR (HPV) 71
ULTRAVIOLET (UV) LIGHT DISINFECTION 71
WATER TREATMENT 71
DESIGN OF SINKS AND OTHER WATER FACILITIES 71
LEVELS OF CLEANING 72
ENVIRONMENTAL CLEANING 72
DISINFECTION 72
Levels of Disinfection 72
TABLE 24 ADVANTAGES/DISADVANTAGES OF COMMONLY USED DISINFECTANTS 73
Disinfectants 75
Phenolics 75
Oxidizing Agents 75
Halogens 75
Aldehydes 75
Ortho-phthalaldehyde (OPA) 76
Quaternary Ammonium Compounds 76
Bleach 76
Alcohols 76
TABLE 25 PROJECTED GLOBAL MARKET FOR DISINFECTANT PRODUCTS DESIGNED
TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 ($ MILLIONS) 77
FIGURE 9 GLOBAL MARKET SHARES OF DISINFECTANT PRODUCTS BY TYPE, 2012
(%) 77
Patient Skin Preparation Disinfectants 77
Povidone-Iodine Solutions 78
Chlorohexidine Gluconate 78
TABLE 26 PROJECTED GLOBAL MARKET FOR PATIENT PREPARATION
DISINFECTANTS, THROUGH 2018 ($ MILLIONS) 79
STERILIZATION SYSTEMS FOR INFECTION CONTROL 79
TABLE 27 PROJECTED GLOBAL MARKET FOR STERILIZATION DESIGNED TO
MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 ($ MILLIONS) 79
FILTRATION 80
CHEMICAL STERILIZATION 80
EtO Sterilization 81
Major Manufacturers in Chemical Sterilization 81
STEAM STERILIZATION 81
TABLE 28 SELECTED MATERIALS THAT RESPOND WELL TO STEAM STERILIZATION 82
Autoclaving 82
Major Players in Heat Sterilization 82
ANTIMICROBIAL COPPER SURFACE COATINGS 82
REGIONAL ANALYSIS 83
TABLE 29 PROJECTED GLOBAL MARKET FOR ENVIRONMENTAL
PRODUCTS/EQUIPMENT TO CONTROL HAI BY REGION, THROUGH 2018 ($ MILLIONS) 83
FIGURE 10 GLOBAL MARKET SHARES OF ENVIRONMENTAL PRODUCTS TO MINIMIZE
HAI BY PRODUCT, 2013 AND 2018 (%) 83
AMERICAS 84
TABLE 30 PROJECTED AMERICAS MARKET FOR ENVIRONMENTAL
PRODUCTS/EQUIPMENT TO CONTROL HAI BY REGION, THROUGH 2018 ($ MILLIONS) 85
TABLE 31 PROJECTED AMERICAS MARKET FOR ENVIRONMENTAL PRODUCTS
DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 ($
MILLIONS)
85
EMRA 85
TABLE 32 PROJECTED EMRA MARKET FOR ENVIRONMENTAL
PRODUCTS/EQUIPMENT TO CONTROL HAI BY REGION, THROUGH 2018 ($ MILLIONS) 86
TABLE 33 PROJECTED EMRA MARKET FOR ENVIRONMENTAL PRODUCTS DESIGNED
TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 ($ MILLIONS) 86
FIGURE 11 EMRA MARKET SHARE OF ENVIRONMENTAL PRODUCTS TO MINIMIZE
HAI BY PRODUCT, 2013 AND 2018 (%) 86
ASIA 87
TABLE 34 PROJECTED ASIAN MARKET FOR ENVIRONMENTAL
PRODUCTS/EQUIPMENT TO CONTROL HAI, THROUGH 2018 ($ MILLIONS) 88
TABLE 35 PROJECTED ASIAN MARKET FOR ENVIRONMENTAL PRODUCTS DESIGNED
TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 ($ MILLIONS) 88
FIGURE 12 ASIAN MARKET SHARE OF ENVIRONMENTAL PRODUCTS TO MINIMIZE
HAI BY PRODUCT, 2013 AND 2018 (%) 88

CHAPTER 6 HAI MEDICAL DEVICES: CATHETERS, PATIENT VENTILATION SYSTEMS AND IN-LINE STERILIZATION FILTERS 91

TABLE 36 PROJECTED GLOBAL MARKET FOR MEDICAL DEVICES THAT MINIMIZE
HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 ($ MILLIONS) 91
ANTIMICROBIAL COATINGS 91
CATHETERS 91
CATHETER COATINGS 92
Common Antimicrobial Coatings 92
Nitrofurazone 93
Minocycline/Rifampin 93
Silver Coating 93
SURFACE-MODIFIED CATHETER 93
GLOBAL HAI CATHETER MARKET 94
TABLE 37 PROJECTED GLOBAL MARKET FOR CATHETERS WITH ANTIMICROBIAL
PROPERTIES, THROUGH 2018 ($ MILLIONS) 94
FIGURE 13 PROJECTED HAI CATHETER MARKET SHARES BY URINARY, CVC, PICC,
2013 AND 2018 (%) 95
URINARY TRACT CATHETERS 95
CENTRAL VENOUS CATHETERS 96
Dialysis Catheters 96
Catheter-Related Bloodstream Infections (CRBSI) 96
PERIPHERALLY INSERTED CENTRAL VENOUS CATHETERS (PICC) 97
MARKET OPPORTUNITIES FOR CATHETER MANUFACTURERS 97
CATHETER GROWTH IN REGIONAL MARKETS 97
TABLE 38 PROJECTED GLOBAL HAI CATHETER MARKET BY REGION, THROUGH
2018 ($ MILLIONS) 98
FIGURE 14 PROJECTED GLOBAL HAI CATHETER MARKET SHARES BY REGION, 2013
AND 2018 (%) 98
PATIENT VENTILATION DEVICES 99
TABLE 39 PROJECTED GLOBAL MARKET FOR PATIENT VENTILATION PRODUCTS,
THROUGH 2018 ($ MILLIONS) 100
TYPES OF VENTILATION DEVICES 100
Noninvasive Ventilators 100
PATIENT VENTILATION MARKET 101
TABLE 40 PROJECTED GLOBAL MARKET FOR NONINVASIVE VENTILATION SYSTEMS
FOR USE WITH PATIENTS WHO HAVE HAI, THROUGH 2018 ($ MILLIONS) 101
ENDOTRACHEAL TUBES AND VENTILATION SYSTEMS 101
Coated Endotracheal Tubes 101
Tapered Endotracheal Tubes 102
TABLE 41 PROJECTED GLOBAL MARKET FOR COATED ENDOTRACHEAL TUBES
DESIGNED TO MINIMIZE VAP, THROUGH 2018 ($ MILLIONS) 102
IN-LINE STERILE IV FILTRATION 102
TABLE 42 PROJECTED GLOBAL STERILE IV FILTER MARKET, THROUGH 2018 ($
MILLIONS) 103
REGIONAL ANALYSIS 103
TABLE 43 PROJECTED GLOBAL MARKET FOR PATIENT INFECTION CONTROL
DEVICES BY REGION, THROUGH 2018 ($ MILLIONS) 103
FIGURE 15 GLOBAL HAI PATIENT INFECTION CONTROL DEVICES MARKET SHARES
BY REGION, 2013 AND 2018 (%) 104
THE AMERICAS 105
TABLE 44 PROJECTED AMERICAS MARKET FOR HAI INFECTION CONTROL DEVICES
BY REGION, THROUGH 2018 ($ MILLIONS) 105
FIGURE 16 AMERICAS MARKET SHARES FOR CATHETERS, PATIENT VENTILATION
SYSTEMS AND IN-LINE STERILE FILTERS, 2013 AND 2018 (%) 105
TABLE 45 PROJECTED AMERICAS MARKET FOR CATHETERS, PATIENT VENTILATION
SYSTEMS AND IN-LINE STERILE FILTERS, THROUGH 2018 ($ MILLIONS) 107
FIGURE 17 AMERICAS MARKET SHARES OF CATHETERS, PATIENT VENTILATION
SYSTEMS AND IN-LINE STERILE FILTERS BY PRODUCT, 2013 AND 2018 (%) 107
EMRA 108
TABLE 46 PROJECTED EMRA MARKET FOR CATHETERS, PATIENT VENTILATION
SYSTEMS AND IN-LINE STERILE FILTERS BY REGION, THROUGH 2018 ($ MILLIONS) 108
TABLE 47 PROJECTED EMRA MARKET FOR CATHETERS, PATIENT VENTILATION
SYSTEMS AND IN-LINE STERILE FILTERS, THROUGH 2018 ($ MILLIONS) 109
FIGURE 18 EMRA MARKET SHARES OF CATHETERS, PATIENT VENTILATION
SYSTEMS AND IN-LINE STERILE FILTERS BY PRODUCT, 2013 AND 2018 (%) 109
ASIA 110
TABLE 48 PROJECTED ASIAN MARKET FOR CATHETERS, PATIENT VENTILATION
SYSTEMS AND IN-LINE STERILE FILTERS BY REGION, THROUGH 2018 ($ MILLIONS) 110
TABLE 49 PROJECTED ASIAN MARKET FOR CATHETERS, PATIENT VENTILATION
SYSTEMS AND IN-LINE STERILE FILTERS, THROUGH 2018 ($ MILLIONS) 111
FIGURE 19 ASIAN MARKET SHARES OF CATHETERS, PATIENT VENTILATION
SYSTEMS AND IN-LINE STERILE FILTERS BY PRODUCT, 2013 AND 2018 (%) 111

CHAPTER 7 REGULATIONS 114

AMERICAS 114
CREATING DRUG TREATMENTS 114
TABLE 50 PROCESS OF CREATING DRUG TREATMENTS IN THE U.S. 114
U.S. INFECTION CONTROL PROGRAMS 115
INFECTION CONTROL MEASURES/PROTOCOLS 115
U.S. REGULATIONS 116
HOSPITAL INFECTIONS DISCLOSURE ACT (HIDA) 116
CURRENT AND PENDING REQUIREMENTS 116
Affordable Care Act and Implications for the Pharmaceutical Industry 116
Biosimilars 117
CMS Reimbursement for HAI 117
"Never Events" Reimbursement 117
Generating Antibiotics Incentives Now Act (2012) 118
BRAZILIAN REGULATIONS 118
EUROPEAN REGULATIONS 119
INNOVATIVE MEDICINES INITIATIVE (IMI) 119
IMPLICATIONS FOR PHARMACEUTICAL MANUFACTURERS 119
JAPANESE REGULATIONS 119
CHINESE REGULATIONS 120

CHAPTER 8 CURRENT RESEARCH, EMERGING THERAPIES AND MARKET

OPPORTUNITIES 122
EMERGING RESEARCH 122
FIMD 122
BROAD SPECTRUM ANTIVIRAL 122
NEW ENGLAND CENTER OF EXCELLENCE (NERCE) 123
PHARMACEUTICAL TREATMENT PRODUCT PIPELINE 123
TABLE 51 HAI PHARMACEUTICAL PRODUCT PIPELINE 123
FIGURE 20 MARKET SHARES BY TYPE OF PHARMACEUTICAL COMPOUND IN
DEVELOPMENT, 2012 (%) 127
PHARMACEUTICAL RESEARCH 129
BACTERIAL INFECTIONS: APPROVED TREATMENTS AND PRODUCTS IN
DEVELOPMENT 129
Achaogen 129
Rib-X Pharmaceuticals 129
Wakamoto Pharmaceutical Co. Ltd. 129
GlaxoSmithKline (GSK) 129
Polyphor 130
Rempex Pharmaceuticals 130
Basilea Pharmaceuticals 130
Cerexa 130
Cubist Pharmaceuticals 131
Merck 131
Galapagos NV 131
Optimer Pharmaceuticals 132
GlaxoSmithKline 132
Toyama Chemical 132
Trius Therapeutics 132
Crestone Pharma 133
Boehringer Ingelheim 133
Theravance 133
The Medicines Company 134
Paratek Pharmaceuticals 134
VIRAL INFECTIONS: APPROVED TREATMENTS AND PRODUCTS IN
DEVELOPMENT 134
BioCryst Pharmaceuticals 134
ViiV Healthcare 134
Roche 135
Merck 135
Toyama Chemical 135
Daiichi Sankyo 136
Gilead Sciences 136
Janssen Pharmaceuticals/Johnson & Johnson 136
Vertex 136
FUNGAL INFECTIONS: APPROVED TREATMENTS AND PRODUCTS IN
DEVELOPMENT 136
Basilea Pharmaceuticals 136
ANTISEPTIC WASHES 137
MEDICAL DEVICE DESIGN 137
ANTIBACTERIAL, ANTIFOULING POLYMER COATINGS 137
ONDINE BIOMEDICAL 137
OPPORTUNITIES/CHALLENGES FOR HAI INDUSTRY 138
MEDICAL DEVICE OPPORTUNITIES/CHALLENGES 138
Challenges 138
ENVIRONMENTAL AND STRUCTURAL OPPORTUNITIES/CHALLENGES 139
Challenges 139
PHARMACEUTICAL MARKET OPPORTUNITIES/CHALLENGES 139
Patent Expiry 140
TABLE 52 SELECTED HAI-RELATED PHARMACEUTICAL PATENT EXPIRATIONS,
2005–2015 140
Pipeline Limitations 140
Regulatory Restrictions 141
Generic Competition 141
THE IMPACT OF DEMOGRAPHIC CHANGES 141
DEMOGRAPHIC CHANGES IN THE U.S. 141
DEMOGRAPHIC CHANGES OUTSIDE THE U.S. 142

CHAPTER 9 PATENTS 144

TABLE 53 NUMBER OF SELECTED PATENTS BY TYPE, 2008 THROUGH JULY 2013 144
PATENTS BY DATE OF ISSUE 144
TABLE 54 PHARMACEUTICAL PATENTS BY DATE OF ISSUE, JAN. 2008 THROUGH
JULY 2013 145
TABLE 55 ENVIRONMENTAL PATENTS BY DATE OF ISSUE, JAN. 2008 THROUGH JULY
2013 145
TABLE 56 MEDICAL DEVICE* PATENTS BY DATE OF ISSUE, JAN. 2008 THROUGH
JULY 2013 145
NUMBER OF PATENTS BY MANUFACTURER 145
TABLE 57 NUMBER OF PATENTS BY MANUFACTURER, JAN. 2008 THROUGH JULY
2013 146
PHARMACEUTICALS 148
BACTERIAL PHARMACEUTICAL PATENTS 148
TABLE 58 PATENTS ON BACTERIAL PHARMACEUTICALS: NUMBER, COMPANY, TYPE
OF PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE, JAN. 2008 THROUGH JULY
2013
149
FUNGAL PHARMACEUTICAL PATENTS 160
TABLE 59 PATENTS ON FUNGAL PHARMACEUTICALS: NUMBER, COMPANY, TYPE OF
PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE, JANUARY 2010 THROUGH
DECEMBER 2012
160
VIRAL PHARMACEUTICAL PATENTS 160
TABLE 60 PATENTS ON VIRAL PHARMACEUTICALS: NUMBER, COMPANY, TYPE OF
PHARMACEUTICAL, DESCRIPTION, JAN. 2008 THROUGH JULY 2013 161
ENVIRONMENTAL CONTROLS 162
TABLE 61 PATENTS ON AIR FILTRATION: NUMBER, COMPANY, TYPE OF
PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE JULY 2012-MARCH 2013 163
TABLE 62 PATENTS ON WATER TREATMENT: NUMBER, COMPANY, TYPE OF
PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE SEPT. 2010 TO JUNE 2013 164
TABLE 63 PATENTS ON SOLID WASTE TREATMENT: NUMBER, COMPANY, TYPE OF
PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE APRIL 2013 165
PATENTS FOR PATIENT DISINFECTION 166
TABLE 64 PATENTS ON PATIENT DISINFECTANTS: NUMBER, COMPANY, TYPE OF
PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE, JAN. 2008 TO JULY 2013 166
PATENTS FOR SURFACE DISINFECTANTS 167
TABLE 65 PATENTS ON SURFACE DISINFECTANTS: NUMBER, COMPANY, TYPE OF
PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE, JAN. 2008 TO JULY 2013 167
MEDICAL DEVICES 172
TABLE 66 PATENTS ON CATHETERS: NUMBER, COMPANY, TYPE OF
PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE, JANUARY 2008 TO JULY 2012 172
Antimicrobial Coatings 176
TABLE 67 PATENTS ON ANTIMICROBIAL COATINGS: NUMBER, COMPANY, TYPE OF
PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE, JAN. 2008 THROUGH JUNE 2013 177

CHAPTER 10 COMPANY DIRECTORY 187

PHARMACEUTICALS 187
ABBOTT LABORATORIES 187
Business Overview 187
Products 187
TABLE 68 ABBOTT HAI PRODUCTS 187
ACHAOGEN INC. 188
ASTELLAS PHARMA INC. 188
Business Overview 188
Products 188
TABLE 69 ASTELLAS HAI PRODUCTS 188
ASTRAZENECA PLC 189
Business Overview 189
Products 189
TABLE 70 ASTRAZENECA HAI PRODUCTS 189
B. BRAUN MELSUNGEN 189
Business Overview 189
Products 190
TABLE 71 B. BRAUN HAI PRODUCTS 190
BACTIGUARD AB 190
Business Overview 190
Products 190
BASILEA PHARMACEUTICA LTD. 191
Business Overview 191
Products 191
BAXTER INTERNATIONAL 191
Business Overview 191
BAYER AG (MILES-BAYER) 192
Business Overview 192
Products 192
TABLE 72 BAYER HAI PRODUCTS 192
BOEHRINGER INGELHEIM GMBH 192
Business Overview 193
Products 193
TABLE 73 BOEHRINGER INGELHEIM HAI PRODUCTS 193
BRISTOL-MYERS SQUIBB 193
Business Overview 193
Products 194
TABLE 74 BRISTOL MYERS SQUIBB HAI PRODUCTS 194
CEREXA INC. (FOREST LABORATORIES) 194
Business Overview 194
Products 194
TABLE 75 CEREXA HAI PRODUCTS 194
CUBIST PHARMACEUTICALS 195
Business Overview 195
Products 195
TABLE 76 CUBIST HAI PRODUCTS 195
DAIICHI SANKYO 195
Business Overview 195
Products 196
TABLE 77 DAIICHI SANKYO HAI PRODUCT 196
FOREST LABORATORIES 196
Business Overview 196
Products 196
TABLE 78 FOREST LABORATORIES HAI PRODUCTS 196
GILEAD SCIENCES 196
Business Overview 197
Products 197
TABLE 79 GILEAD SCIENCES HAI PRODUCTS 197
GLAXOSMITHKLINE 197
Business Overview 197
Products 198
TABLE 80 GLAXOSMITHKLINE HAI PRODUCTS 198
JOHNSON & JOHNSON 198
Business Overview 198
Products 199
TABLE 81 JOHNSON & JOHNSON HAI PRODUCTS 199
JANSSEN THERAPEUTICS (FORMERLY TIBOTEC THERAPEUTICS) 199
Business Overview 199
Products 200
TABLE 82 JANSSEN THERAPEUTICS HAI PRODUCTS 200
MERCK 200
Business Overview 200
Products 200
TABLE 83 MERCK HAI PRODUCTS 200
NOVARTIS PHARMACEUTICALS 201
Business Overview 201
Products 201
TABLE 84 NOVARTIS HAI PRODUCTS 201
PFIZER 202
Business Overview 202
Products 202
TABLE 85 PFIZER HAI PRODUCTS 202
REMPEX PHARMACEUTICALS 203
Business Overview 203
RIB-X PHARMACEUTICALS 203
Business Overview 203
ROCHE PHARMACEUTICALS 204
Business Overview 204
Products 204
TABLE 87 ROCHE HAI PHARMACEUTICAL PRODUCTS 204
ROMARK LABORATORIES 204
Business Overview 204
SCHERING-PLOUGH (SEE MERCK) 205
TETRAPHASE PHARMACEUTICALS 205
Business Overview 205
THERAVANCE 205
Business Overview 205
Products 206
TABLE 88 THERAVANCE HAI PRODUCTS 206
TOYAMA CHEMICAL CO. LTD. 206
Business Overview 206
Products 206
TABLE 89 TOYAMA CHEMICAL HAI PRODUCTS 206
VENUS REMEDIES LTD. 207
Business Overview 207
Products 207
TABLE 90 VENUS REMEDIES HAI PRODUCTS 207
VERTEX PHARMACEUTICALS INC. 207
Business Overview 207
Products 208
TABLE 91 VERTEX HAI PRODUCTS 208
VIIV HEALTHCARE 208
Business Overview 208
Products 208
TABLE 92 VII HEALTHCARE HAI PRODUCTS 208
VIROPHARMA INC. 209
Business Overview 209
Products 209
TABLE 93 VIROPHARMA HAI PRODUCTS 209
ENVIRONMENTAL PRODUCTS 209
3M HEALTHCARE, MEDICAL DIVISION 209
Business Overview 209
Products 210
ADVANCED STERILIZATION PRODUCTS 210
Business Overview 210
Products 210
ANDERSEN PRODUCTS INC. 211
Business Overview 211
Products 211
ECOLAB 211
Business Overview 211
Products 211
GETINGE USA INC. 212
Business Overview 212
Products 212
PRIMUS STERILIZER CO. INC. 212
Business Overview 212
Products 212
RUHOF CORP. 213
Business Overview 213
Products 213
STERIGENICS INTERNATIONAL INC. 213
Business Overview 213
Products 213
SEALED AIR CORP. (DIVERSEY INC.) 214
Business Overview 214
Products 214
STERIS CORP. 214
Business Overview 214
Products 214
TUTTNAUER USA CO. LTD. 215
Business Overview 215
Products 215
ULTRAVIOLET DEVICES INC. 215
Business Overview 215
Products 215
XENEX HEALTHCARE SERVICES 216
Business Overview 216
Products 216
INFECTION CONTROL DEVICES 216
B BRAUN MELSUNGEN AG 216
Business Overview 217
Products 217
BECTON DICKINSON 217
Business Overview 217
Products 217
CANTEL MEDICAL CORP. 218
Business Overview 218
Products 218
CAREFUSION CORP. 219
Business Overview 219
Products 219
CLOROX CO. 219
Business Overview 219
Products 219
COLOPLAST GROUP 220
Business Overview 220
Products 220
COOK MEDICAL 220
Business Overview 220
Products 220
COVIDIEN PLC 221
Business Overview 221
Products 221
C.R. BARD 221
Business Overview 221
Products 222
KIMBERLY-CLARK HEALTHCARE 222
Business Overview 222
Products 222
ONDINE BIOMEDICAL INC. 222
Business Overview 222
Products 223
ROCHESTER MEDICAL LTD. 223
Business Overview 223
Products 223
TELEFLEX MEDICAL 223
Business Overview 223
Products 224
WELCH ALLYN INC. 224
Business Overview 224
Products 224
WELLSPECT HEALTHCARE (FORMERLY ASTRA TECH INC.) 224

LIST OF TABLES

SUMMARY TABLE GLOBAL MARKET FOR SELECTED HAI TREATMENTS, THROUGH
2018 ($ MILLIONS) 7
TABLE 1 CAUSES AND TYPES OF HEALTHCARE-ACQUIRED INFECTIONS 12
TABLE 2 SELECTED RESPONSIBILITIES OF INFECTION CONTROL TEAM MEMBERS 24
TABLE 3 MAIN STEPS AND COMPONENTS IN DEVELOPING AN EFFECTIVE INFECTION
CONTROL SURVEILLANCE SYSTEM 26
TABLE 4 CDC MEASURES FOR PREVENTION OF HEALTHCARE-ACQUIRED INFECTIONS 30
TABLE 5 GOALS TO REDUCE HAI IN U.S. HOSPITALS BY 2013 32
TABLE 6 DECREASE IN HAI IN U.S. HOSPITAL SETTINGS, 2008–2010 (%) 32
TABLE 7 SELECTED MERGERS AND/OR ACQUISITIONS, 2008-2013 ($ MILLIONS) 36
TABLE 8 PROJECTED GLOBAL MARKET FOR HAI PHARMACEUTICALS BY TYPE,
THROUGH 2018 ($ MILLIONS) 39
TABLE 9 SELECTED VIRAL HAI PHARMACEUTICALS BY NAME, INDICATION AND
MANUFACTURER, 2010 40
TABLE 10 PROJECTED GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT VIRAL
HAI BY CONDITION, THROUGH 2018 ($ MILLIONS) 44
TABLE 11 ANTIBIOTIC RESISTANT ORGANISMS AND DRUG CLASSES AFFECTED 49
TABLE 12 SELECTED BACTERIAL HAI PHARMACEUTICALS BY NAME, INDICATION AND
MANUFACTURER, 2012 49
TABLE 13 PROJECTED GLOBAL MARKET FOR TO TREAT BACTERIAL HAI, THROUGH
2018 ($ MILLIONS) 56
TABLE 14 SELECT LISTING OF PHARMACEUTICALS TO TREAT FUNGAL INFECTIONS
BY NAME, TYPE AND MANUFACTURER, 2012 56
TABLE 15 PROJECTED GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT FUNGAL
HAI, THROUGH 2018 ($ MILLIONS) 57
TABLE 16 PROJECTED GLOBAL MARKET FOR HAI PHARMACEUTICALS BY REGION,
THROUGH 2018 ($ MILLIONS) 59
TABLE 17 PROJECTED AMERICAS MARKET FOR PHARMACEUTICAL PRODUCTS TO
CONTROL HAI BY REGION, THROUGH 2018 ($ MILLIONS) 60
TABLE 18 PROJECTED AMERICAS MARKET FOR PHARMACEUTICAL PRODUCTS
DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 ($
MILLIONS)
60
TABLE 19 PROJECTED EMRA MARKET FOR PHARMACEUTICAL PRODUCTS TO
CONTROL HAI BY REGION, THROUGH 2018 ($ MILLIONS) 62
TABLE 20 PROJECTED EMRA MARKET FOR PHARMACEUTICAL PRODUCTS DESIGNED
TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS BY TYPE, THROUGH 2018 ($
MILLIONS)
63
TABLE 21 PROJECTED ASIAN MARKET FOR PHARMACEUTICAL PRODUCTS TO
CONTROL HAI, THROUGH 2018 ($ MILLIONS) 65
TABLE 22 PROJECTED ASIAN MARKET FOR PHARMACEUTICAL PRODUCTS DESIGNED
TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS BY TYPE, THROUGH 2018 ($
MILLIONS)
66
TABLE 23 PROJECTED GLOBAL MARKET FOR ENVIRONMENTAL PRODUCTS DESIGNED
TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 ($ MILLIONS) 69
TABLE 24 ADVANTAGES/DISADVANTAGES OF COMMONLY USED DISINFECTANTS 73
TABLE 25 PROJECTED GLOBAL MARKET FOR DISINFECTANT PRODUCTS DESIGNED
TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 ($ MILLIONS) 77
TABLE 26 PROJECTED GLOBAL MARKET FOR PATIENT PREPARATION DISINFECTANTS,
THROUGH 2018 ($ MILLIONS) 79
TABLE 27 PROJECTED GLOBAL MARKET FOR STERILIZATION DESIGNED TO MINIMIZE
HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 ($ MILLIONS) 79
TABLE 28 SELECTED MATERIALS THAT RESPOND WELL TO STEAM STERILIZATION 82
TABLE 29 PROJECTED GLOBAL MARKET FOR ENVIRONMENTAL
PRODUCTS/EQUIPMENT TO CONTROL HAI BY REGION, THROUGH 2018 ($ MILLIONS) 83
TABLE 30 PROJECTED AMERICAS MARKET FOR ENVIRONMENTAL
PRODUCTS/EQUIPMENT TO CONTROL HAI BY REGION, THROUGH 2018 ($ MILLIONS) 85
TABLE 31 PROJECTED AMERICAS MARKET FOR ENVIRONMENTAL PRODUCTS
DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 ($
MILLIONS)
85
TABLE 32 PROJECTED EMRA MARKET FOR ENVIRONMENTAL PRODUCTS/EQUIPMENT
TO CONTROL HAI BY REGION, THROUGH 2018 ($ MILLIONS) 86
TABLE 33 PROJECTED EMRA MARKET FOR ENVIRONMENTAL PRODUCTS DESIGNED
TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 ($ MILLIONS) 86
TABLE 34 PROJECTED ASIAN MARKET FOR ENVIRONMENTAL PRODUCTS/EQUIPMENT
TO CONTROL HAI, THROUGH 2018 ($ MILLIONS) 88
TABLE 35 PROJECTED ASIAN MARKET FOR ENVIRONMENTAL PRODUCTS DESIGNED
TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 ($ MILLIONS) 88
TABLE 36 PROJECTED GLOBAL MARKET FOR MEDICAL DEVICES THAT MINIMIZE
HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 ($ MILLIONS) 91
TABLE 37 PROJECTED GLOBAL MARKET FOR CATHETERS WITH ANTIMICROBIAL
PROPERTIES, THROUGH 2018 ($ MILLIONS) 94
TABLE 38 PROJECTED GLOBAL HAI CATHETER MARKET BY REGION, THROUGH 2018
($ MILLIONS) 98
TABLE 39 PROJECTED GLOBAL MARKET FOR PATIENT VENTILATION PRODUCTS,
THROUGH 2018 ($ MILLIONS) 100
TABLE 40 PROJECTED GLOBAL MARKET FOR NONINVASIVE VENTILATION SYSTEMS
FOR USE WITH PATIENTS WHO HAVE HAI, THROUGH 2018 ($ MILLIONS) 101
TABLE 41 PROJECTED GLOBAL MARKET FOR COATED ENDOTRACHEAL TUBES
DESIGNED TO MINIMIZE VAP, THROUGH 2018 ($ MILLIONS) 102
TABLE 42 PROJECTED GLOBAL STERILE IV FILTER MARKET, THROUGH 2018 ($
MILLIONS) 103
TABLE 43 PROJECTED GLOBAL MARKET FOR PATIENT INFECTION CONTROL DEVICES
BY REGION, THROUGH 2018 ($ MILLIONS) 103
TABLE 44 PROJECTED AMERICAS MARKET FOR HAI INFECTION CONTROL DEVICES BY
REGION, THROUGH 2018 ($ MILLIONS) 105
TABLE 45 PROJECTED AMERICAS MARKET FOR CATHETERS, PATIENT VENTILATION
SYSTEMS AND IN-LINE STERILE FILTERS, THROUGH 2018 ($ MILLIONS) 107
TABLE 46 PROJECTED EMRA MARKET FOR CATHETERS, PATIENT VENTILATION
SYSTEMS AND IN-LINE STERILE FILTERS BY REGION, THROUGH 2018 ($ MILLIONS) 108
TABLE 47 PROJECTED EMRA MARKET FOR CATHETERS, PATIENT VENTILATION
SYSTEMS AND IN-LINE STERILE FILTERS, THROUGH 2018 ($ MILLIONS) 109
TABLE 48 PROJECTED ASIAN MARKET FOR CATHETERS, PATIENT VENTILATION
SYSTEMS AND IN-LINE STERILE FILTERS BY REGION, THROUGH 2018 ($ MILLIONS) 110
TABLE 49 PROJECTED ASIAN MARKET FOR CATHETERS, PATIENT VENTILATION
SYSTEMS AND IN-LINE STERILE FILTERS, THROUGH 2018 ($ MILLIONS) 111
TABLE 50 PROCESS OF CREATING DRUG TREATMENTS IN THE U.S. 114
TABLE 51 HAI PHARMACEUTICAL PRODUCT PIPELINE 123
TABLE 52 SELECTED HAI-RELATED PHARMACEUTICAL PATENT EXPIRATIONS,
2005–2015 140
TABLE 53 NUMBER OF SELECTED PATENTS BY TYPE, 2008 THROUGH JULY 2013 144
TABLE 54 PHARMACEUTICAL PATENTS BY DATE OF ISSUE, JAN. 2008 THROUGH JULY
2013 145
TABLE 55 ENVIRONMENTAL PATENTS BY DATE OF ISSUE, JAN. 2008 THROUGH JULY
2013 145
TABLE 56 MEDICAL DEVICE* PATENTS BY DATE OF ISSUE, JAN. 2008 THROUGH JULY
2013 145
TABLE 57 NUMBER OF PATENTS BY MANUFACTURER, JAN. 2008 THROUGH JULY
2013 146
TABLE 58 PATENTS ON BACTERIAL PHARMACEUTICALS: NUMBER, COMPANY, TYPE
OF PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE, JAN. 2008 THROUGH JULY
2013
149
TABLE 59 PATENTS ON FUNGAL PHARMACEUTICALS: NUMBER, COMPANY, TYPE OF
PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE, JANUARY 2010 THROUGH
DECEMBER 2012
160
TABLE 60 PATENTS ON VIRAL PHARMACEUTICALS: NUMBER, COMPANY, TYPE OF
PHARMACEUTICAL, DESCRIPTION, JAN. 2008 THROUGH JULY 2013 161
TABLE 61 PATENTS ON AIR FILTRATION: NUMBER, COMPANY, TYPE OF
PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE JULY 2012-MARCH 2013 163
TABLE 62 PATENTS ON WATER TREATMENT: NUMBER, COMPANY, TYPE OF
PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE SEPT. 2010 TO JUNE 2013 164
TABLE 63 PATENTS ON SOLID WASTE TREATMENT: NUMBER, COMPANY, TYPE OF
PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE APRIL 2013 165
TABLE 64 PATENTS ON PATIENT DISINFECTANTS: NUMBER, COMPANY, TYPE OF
PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE, JAN. 2008 TO JULY 2013 166
TABLE 65 PATENTS ON SURFACE DISINFECTANTS: NUMBER, COMPANY, TYPE OF
PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE, JAN. 2008 TO JULY 2013 167
TABLE 66 PATENTS ON CATHETERS: NUMBER, COMPANY, TYPE OF
PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE, JANUARY 2008 TO JULY 2012 172
TABLE 67 PATENTS ON ANTIMICROBIAL COATINGS: NUMBER, COMPANY, TYPE OF
PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE, JAN. 2008 THROUGH JUNE 2013 177
TABLE 68 ABBOTT HAI PRODUCTS 187
TABLE 69 ASTELLAS HAI PRODUCTS 188
TABLE 70 ASTRAZENECA HAI PRODUCTS 189
TABLE 71 B. BRAUN HAI PRODUCTS 190
TABLE 72 BAYER HAI PRODUCTS 192
TABLE 73 BOEHRINGER INGELHEIM HAI PRODUCTS 193
TABLE 74 BRISTOL MYERS SQUIBB HAI PRODUCTS 194
TABLE 75 CEREXA HAI PRODUCTS 194
TABLE 76 CUBIST HAI PRODUCTS 195
TABLE 7

Read the full report:
Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products

http://www.reportbuyer.com/pharma_healthcare/healthcare/healthcare_acquired_infection.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer